Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | HTT | P42858 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 4/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CASP9 | P55211 | 2/20 | 0.49 |
| ▸ | CASP6 | P55212 | 2/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7036575 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| Cyclooctanol SCHEMBL5303490 | 0.84 | RAB9A (0.60) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL9625815 | 0.82 | LMNA (0.45) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL1937600 | 0.82 | LMNA (0.54) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL2118284 | 0.82 | ATM (0.55) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL23529356 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL6736049 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL23561312 | 0.82 | LMNA (0.48) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL1483376 | 0.81 | ALDH1A1 (0.55) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL28774615 | 0.81 | LMNA (0.48) | SMN1; SMN2HTTLMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118420547-B | Radiotherapy sensitizer and preparation method and application thereof | 苏州大学 | 2025-06-03 | — | — | CN | claimed |
| CN-118420547-A | Radiotherapy sensitizer and preparation method and application thereof | 苏州大学 | 2024-08-02 | — | — | CN | claimed |
| CN-117153573-B | Graphene reinforced aluminum-based supercapacitor current collector and preparation method thereof | 深圳特新界面科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-117153573-A | Graphene reinforced aluminum-based supercapacitor current collector and preparation method thereof | 深圳特新界面科技有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-109280044-B | Raltitrexed impurity C and preparation and application thereof | 南京正大天晴制药有限公司 | 2021-04-02 | — | — | CN | claimed |
| CN-109283263-B | Determination method for Raltitrexed synthesis quality control | 南京正大天晴制药有限公司 | 2019-06-25 | — | — | CN | claimed |
| CN-107616976-B | A kind of pharmaceutical composition of Raltitrexed and preparation method thereof | 南京正大天晴制药有限公司 | 2019-06-21 | — | — | CN | claimed |
| CN-109283263-A | Determination method for Raltitrexed synthesis quality control | 南京正大天晴制药有限公司 | 2019-01-29 | — | — | CN | claimed |
| CN-109280044-A | Raltitrexed impurity C and its preparation and application | 南京正大天晴制药有限公司 | 2019-01-29 | — | — | CN | claimed |
| CN-107400110-A | The impurity B of Raltitrexed and its preparation and application | 南京正大天晴制药有限公司 | 2017-11-28 | — | — | CN | claimed |
| CN-101500986-A | Di-aryl substituted amides as GLYT1 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-08-05 | — | — | CN | claimed |
| EP-2066620-A1 | DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | claimed |
| US-20080076806-A1 | Di-aromatic substituted amides as inhibitors for GlyT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | US | claimed |
| WO-2008022938-A1 | DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-28 | — | — | WO | claimed |
| CN-1223593-C | Preparation of Leiliqusai | LUNAN PHARM CO LTD (CN) | 2005-10-19 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| CN-1552709-A | Preparation of Leiliqusai | 鲁南制药股份有限公司 | 2004-12-08 | — | — | CN | claimed |
| EP-0186252-B1 | USE OF THIOPHENE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT AGAINST TUMOURS | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1992-04-01 | — | — | EP | claimed |
| US-4220793-A | Process for preparing a thiophene derivative | LABAZ (FR) | 1980-09-02 | — | — | US | claimed |
| US-12622896-B2 | Antiviral compounds, compositions and methods of use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-12 | — | — | US | disclosed |
| US-20260125356-A1 | TREATMENT OF LEISHMANIASIS | THE UNIV OF DURHAM (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-3597184-B1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2026-03-04 | — | — | EP | disclosed |
| US-12415793-B2 | Modulators of TMEM16A for treating respiratory disease | TMEM16A LIMITED (GB) | 2025-09-16 | — | — | US | disclosed |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| EP-4605086-A1 | TREATMENT OF LEISHMANIASIS | The University of Durham (GB) | 2025-08-27 | — | — | EP | disclosed |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2025-08-07 | — | — | US | disclosed |
| CN-114763346-B | Compounds for inducing cartilage formation and application thereof | 华东师范大学 | 2025-06-10 | — | — | CN | disclosed |
| CN-118420547-B | Radiotherapy sensitizer and preparation method and application thereof | 苏州大学 | 2025-06-03 | — | — | CN | disclosed |
| US-20250114466-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2025-04-10 | — | — | US | disclosed |
| CN-119330982-A | Azetidine compound and medical application thereof | 中国科学院上海药物研究所 | 2025-01-21 | — | — | CN | disclosed |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4457229-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | Byondis B.V. (NL) | 2024-11-06 | — | — | EP | disclosed |
| CN-118613484-A | Antifolate linker-drug and antibody-drug conjugates | 拜奥迪斯私人有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-08-22 | — | — | US | disclosed |
| CN-114269433-B | Modulators of TMEM16A for the treatment of respiratory diseases | TMEM16A有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-116023359-B | Synthesis method of aminothiophene compound and aminothiophene compound | 上海泰坦科技股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118420547-A | Radiotherapy sensitizer and preparation method and application thereof | 苏州大学 | 2024-08-02 | — | — | CN | disclosed |
| CN-117486882-B | Matrine alkaloid derivative and application thereof in preparation of multi-target multi-organ tissue cell injury inhibitor | 吉林农业大学 | 2024-06-11 | — | — | CN | disclosed |
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024084186-A1 | TREATMENT OF LEISHMANIASIS | THE UNIVERSITY OF DURHAM (GB) | 2024-04-25 | — | — | WO | disclosed |
| CN-117903125-A | Preparation method of raltitrexed | 无锡紫杉药业股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240109850-A1 | Covalent PPARG inverse-agonists | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | US | disclosed |
| EP-4037685-B9 | QUINOLINE THAT MODULATE SERCA AND ITS USE FOR TREATING DISEASE | NEURODON CORP (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117486882-A | Matrine alkaloid derivative and application thereof in preparation of multi-target multi-organ tissue cell injury inhibitor | 吉林农业大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-117153573-B | Graphene reinforced aluminum-based supercapacitor current collector and preparation method thereof | 深圳特新界面科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-01-18 | — | — | US | disclosed |
| CN-117327060-A | Preparation method of intermediate impurity of raltitrexed | 无锡紫杉药业股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117298108-A | Androgen receptor and glucocorticoid receptor dual-target inhibitor and application thereof | 浙江师范大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-113292539-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117153573-A | Graphene reinforced aluminum-based supercapacitor current collector and preparation method thereof | 深圳特新界面科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4037685-B1 | QUINOLINE THAT MODULATE SERCA AND ITS USE FOR TREATING DISEASE | NEURODON CORP (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230285382-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2023-09-14 | — | — | US | disclosed |
| CN-116744928-A | Quinolines modulating SERCA and their use for treating diseases | 神经元公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11730729-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023126297-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-07-06 | — | — | WO | disclosed |
| CN-116332885-A | Nitroheterocycle STING agonist, preparation method and application thereof | 中国海洋大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-116209476-A | Antifolate linker-drug and antibody-drug conjugates | 拜奥迪斯私人有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| EP-4175672-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | Byondis B.V. (NL) | 2023-05-10 | — | — | EP | disclosed |
| CN-116023359-A | Synthesis method of aminothiophene compound and aminothiophene compound | 上海泰坦科技股份有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230105935-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-04-06 | — | — | US | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4077320-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | The University of British Columbia (CA) | 2022-10-26 | — | — | EP | disclosed |
| CN-115151536-A | Antiviral compounds, compositions and methods of use | 不列颠哥伦比亚大学 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022020261-A9 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4037685-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | Neurodon Corporation (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114763346-A | Compound for inducing chondrogenesis and application thereof | 华东师范大学 | 2022-07-19 | — | — | CN | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| EP-3983069-A1 | MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-114269433-A | Modulators of TMEM16A for the treatment of respiratory diseases | TMEM16A有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220098164-A1 | MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2022-03-31 | — | — | US | disclosed |
| CN-106957296-B | 5- ((alkoxymethylene) amino) thienyl-2-formyl) -L-glutamic acid dialkyl ester and preparation method thereof | 南京正大天晴制药有限公司 | 2022-03-08 | — | — | CN | disclosed |
| WO-2020249956-A9 | MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2022-03-03 | — | — | WO | disclosed |
| US-11225482-B2 | Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2022-01-18 | — | — | US | disclosed |
| WO-2022008419-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-01-13 | — | — | WO | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| CN-113666907-A | Method for rapidly preparing 4-nitrothiophene-2-formic acid based on microchannel reaction technology | 都创(上海)医药开发有限公司 | 2021-11-19 | — | — | CN | disclosed |
| US-11174253-B2 | Compound and pharmaceutical composition containing the same | ALPHALA CO., LTD. (TW) | 2021-11-16 | — | — | US | disclosed |
| CN-113292539-A | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-108026072-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2021119808-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-06-24 | — | — | WO | disclosed |
| CN-108373476-B | Kinase inhibitor and preparation and application thereof | 成都地奥制药集团有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-105111197-B | Synthesis method of raltitrexed | 上海鼎雅药物化学科技有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-109415367-B | Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-109280044-B | Raltitrexed impurity C and preparation and application thereof | 南京正大天晴制药有限公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-3319956-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020249956-A1 | MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE | Enterprise Therapeutics Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
| EP-3134408-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2020-08-12 | — | — | EP | disclosed |
| CN-111440141-A | Preparation method of hydroxymethyl substituted aromatic heterocyclic compound | 安徽泽升科技有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20200172531-A1 | Novel compound and pharmaceutical composition containing the same | ALPHALA CO., LTD. (TW) | 2020-06-04 | — | — | US | disclosed |
| EP-3478686-B1 | NOVEL DIHYDROPYRROLOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-04-15 | — | — | EP | disclosed |
| WO-2019193540-A1 | HETEROARYL DERIVATIVES OF FORMULA (I) AS ATF4 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-10 | — | — | WO | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20190241570-A1 | NOVEL DIHYDROPYRROLOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-08-08 | — | — | US | disclosed |
| CN-109283262-B | Pass through the method for high efficiency liquid chromatography for separating and determining Raltitrexed and its impurity | 南京正大天晴制药有限公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-109283263-B | Determination method for Raltitrexed synthesis quality control | 南京正大天晴制药有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-109283263-B | Determination method for Raltitrexed synthesis quality control | 南京正大天晴制药有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-107616976-B | A kind of pharmaceutical composition of Raltitrexed and preparation method thereof | 南京正大天晴制药有限公司 | 2019-06-21 | — | — | CN | disclosed |
| EP-2722042-B1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2019-05-29 | — | — | EP | disclosed |
| EP-3478686-A1 | NOVEL DIHYDROPYRROLOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| CN-109415367-A | For treating and preventing hepatitis b virus infected new pyrrolin miazines compound | 豪夫迈·罗氏有限公司 | 2019-03-01 | — | — | CN | disclosed |
| WO-2019028104-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | ALPHALA CO., LTD. (TW) | 2019-02-07 | — | — | WO | disclosed |
| CN-109283263-A | Determination method for Raltitrexed synthesis quality control | 南京正大天晴制药有限公司 | 2019-01-29 | — | — | CN | disclosed |
| CN-109283263-A | Determination method for Raltitrexed synthesis quality control | 南京正大天晴制药有限公司 | 2019-01-29 | — | — | CN | disclosed |
| CN-109283262-A | Pass through the method for high efficiency liquid chromatography for separating and determining Raltitrexed and its impurity | 南京正大天晴制药有限公司 | 2019-01-29 | — | — | CN | disclosed |
| CN-109280044-A | Raltitrexed impurity C and its preparation and application | 南京正大天晴制药有限公司 | 2019-01-29 | — | — | CN | disclosed |
| CN-109280052-A | The related substance F of Raltitrexed and its preparation and application | 南京正大天晴制药有限公司 | 2019-01-29 | — | — | CN | disclosed |
| CN-108976172-A | A kind of 4- pyrimidinediamine micromolecular organic compound and its derivative and its application | 华东师范大学 | 2018-12-11 | — | — | CN | disclosed |
| US-10093683-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-09 | — | — | US | disclosed |
| US-10071995-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-11 | — | — | US | disclosed |
| CN-106032367-B | Chinese cymbidium amine/chinese cymbidium 01 derivatives and its preparation method and application | 华东师范大学 | 2018-08-24 | — | — | CN | disclosed |
| CN-108373476-A | A kind of kinase inhibitor and its preparation and application | 成都地奥制药集团有限公司 | 2018-08-07 | — | — | CN | disclosed |
| EP-3197889-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2018-08-01 | — | — | EP | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| EP-3319956-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-16 | — | — | EP | disclosed |
| CN-108026072-A | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2018-05-11 | — | — | CN | disclosed |
| US-20180127401-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-10 | — | — | US | disclosed |
| CN-107954977-A | The synthetic method of Raltitrexed intermediate | 上海鼎雅药物化学科技有限公司 | 2018-04-24 | — | — | CN | disclosed |
| CN-107721995-A | The relevant material G of Raltitrexed and its preparation and application | 南京正大天晴制药有限公司 | 2018-02-23 | — | — | CN | disclosed |
| US-9890133-B2 | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2018-02-13 | — | — | US | disclosed |
| CN-107616976-A | A kind of pharmaceutical composition of Raltitrexed and preparation method thereof | 南京正大天晴制药有限公司 | 2018-01-23 | — | — | CN | disclosed |
| WO-2018001944-A1 | NOVEL DIHYDROPYRROLOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-04 | — | — | WO | disclosed |
| CN-107400110-A | The impurity B of Raltitrexed and its preparation and application | 南京正大天晴制药有限公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-107400109-A | The impurity A of Raltitrexed and its preparation and application | 南京正大天晴制药有限公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-3197889-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2017-08-02 | — | — | EP | disclosed |
| CN-106957296-A | The formoxyl of 5 ((alkoxymethylene) amino) thienyl 2) L glutamic acid dialkyl esters and preparation method thereof | 南京正大天晴制药有限公司 | 2017-07-18 | — | — | CN | disclosed |
| CN-103764140-B | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | 韩国化学研究院 | 2017-05-17 | — | — | CN | disclosed |
| EP-3134408-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044183-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2017005725-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-12 | — | — | WO | disclosed |
| CN-106032367-A | Vanillylamine/vanillyl alcohol derivatives as well as preparation method and application thereof | 华东师范大学 | 2016-10-19 | — | — | CN | disclosed |
| US-20160297789-A1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-10-13 | — | — | US | disclosed |
| US-9464067-B2 | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) | 2016-10-11 | — | — | US | disclosed |
| US-9440954-B2 | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-13 | — | — | US | disclosed |
| US-9440954-B2 | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-13 | — | — | US | disclosed |
| US-9440954-B2 | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-13 | — | — | US | disclosed |
| EP-2855450-B1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2016-07-06 | — | — | EP | disclosed |
| EP-2855450-B1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2016-07-06 | — | — | EP | disclosed |
| WO-2016046156-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016032569-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | CELLADON CORPORATION (US) | 2016-03-03 | — | — | WO | disclosed |
| CN-105111197-A | Synthesis methods of raltitrexed | SHANGHAI DINGYA PHARMACEUTICAL CHEMICALS CO LTD | 2015-12-02 | — | — | CN | disclosed |
| WO-2015164308-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-29 | — | — | WO | disclosed |
| EP-1636192-B9 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| EP-2855450-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2015-04-08 | — | — | EP | disclosed |
| CN-102206172-B | Substituted diaryl compound and preparation method and antiviral application thereof | INST MED BIOTECHNOLOGY CAMS | 2015-02-25 | — | — | CN | disclosed |
| CN-104334542-A | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | CHIESI FARMA SPA | 2015-02-04 | — | — | CN | disclosed |
| US-8884017-B2 | 2-heteroarylcarboxylic acid amides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| CN-101316853-B | Benzothiazole and thiazolopyridine as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC | 2014-09-24 | — | — | CN | disclosed |
| EP-2324006-B1 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2014-08-13 | — | — | EP | disclosed |
| CN-103764140-A | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | KOREA RES INST CHEM TECH | 2014-04-30 | — | — | CN | disclosed |
| US-20140114068-A1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) | 2014-04-24 | — | — | US | disclosed |
| EP-2722042-A2 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | Korea Research Institute of Chemical Technology (KR) | 2014-04-23 | — | — | EP | disclosed |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| EP-2696683-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | Alzheimer's Institute of America, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2013182451-A9 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-02-06 | — | — | WO | disclosed |
| EP-1636192-B1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2014-01-15 | — | — | EP | disclosed |
| WO-2013182451-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-12-12 | — | — | WO | disclosed |
| US-20130324501-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-12-05 | — | — | US | disclosed |
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | disclosed |
| CN-103145738-A | Imidazo [2,1-b] thiayole derivatives as SIRTUIN modulating compounds | SIRTRIS PHARMACEUTICALS INC | 2013-06-12 | — | — | CN | disclosed |
| CN-101479253-B | Insecticidal compounds | SYNGENTA PARTICIPATIONS AG | 2013-03-13 | — | — | CN | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| EP-1910362-B1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS INC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2166846-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| CN-101500986-B | Di-aryl substituted amides as GLYT1 inhibitors | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | disclosed |
| US-8258119-B2 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | Kasina Laila Innova Pharmaceuticals (IN) | 2012-09-04 | — | — | US | disclosed |
| US-8252936-B2 | Insecticidal compounds | SYNGENTA CROP PROTECTION LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120202842-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2012-08-09 | — | — | US | disclosed |
| EP-2016067-B1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2468752-A1 | Thiazolopyridine derivatives as sirtuin-modulators | Sirtris Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8178536-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8163908-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8093401-B2 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8088928-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| CN-101111483-B | IGF-1R inhibitors | KYOWA HAKKO KIRIN CO.,LTD. (JP) | 2011-12-14 | — | — | CN | disclosed |
| US-8076355-B2 | 2-heteroarylcarboxylic acid amides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-13 | — | — | US | disclosed |
| EP-2388263-A1 | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators | Sirtris Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| CN-101386596-B | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD | 2011-10-26 | — | — | CN | disclosed |
| US-8044198-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| CN-102206172-A | Substituted diaryl compound and preparation method and antiviral application thereof | INST MED BIOTECHNOLOGY CAMS | 2011-10-05 | — | — | CN | disclosed |
| CN-102127063-A | New synthesis technology of anti-cancer drug Raltitrexed | SHENZHEN PUMAIDA TECHNOLOGY CO LTD | 2011-07-20 | — | — | CN | disclosed |
| US-7964645-B2 | Glycine transporter gene 1 (GlyT-1); psychosis, schizophrenia, dementia; activation of NMDA receptors via GlyT-1 inhibition; N-(([(4-chloro-phenyl)-phenyl-methyl]-carbamoyl)-methyl)-4-fluorobenzamide for example | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2324006-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2011-05-25 | — | — | EP | disclosed |
| US-7935724-B2 | Thiophene and benzothiophene hydroxamic acid derivatives | MERCK HDAC RESEARCH, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935724-B2 | Thiophene and benzothiophene hydroxamic acid derivatives | MERCK HDAC RESEARCH, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-7855289-B2 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| WO-2010034740-A1 | (R)-3-(N,N-DIMETHYLAMINO)PYRROLIDINE DERIVATIVES | PALAU PHARMA, S.A. (ES) | 2010-04-01 | — | — | WO | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | LAILA NUTRACEUTICALS (IN) | 2010-03-18 | — | — | US | disclosed |
| WO-2010029577-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | GOKARAJU GANGA RAJU (IN) | 2010-03-18 | — | — | WO | disclosed |
| US-7608629-B2 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| CN-101553486-A | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators | NEUROSEARCH AS (DK) | 2009-10-07 | — | — | CN | disclosed |
| US-7576115-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| CN-101500986-A | Di-aryl substituted amides as GLYT1 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-08-05 | — | — | CN | disclosed |
| US-20090192175-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| CN-101479253-A | Insecticidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| CN-101466686-A | C-FMS kinase inhibitor | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-24 | — | — | CN | disclosed |
| US-7547722-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-06-16 | — | — | US | disclosed |
| US-7547722-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-06-16 | — | — | US | disclosed |
| EP-2066620-A1 | DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20090127515-A1 | PI-CONJUGATED MOLECULES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2009-05-21 | — | — | US | disclosed |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7511070-B2 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009035949-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| CN-101386596-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2009-03-18 | — | — | CN | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
| EP-2016067-A1 | INSECTICIDAL COMPOUNDS | Syngenta Participations AG (CH) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| EP-2014285-A1 | NPYY5 antagonists | Shionogi&Co., Ltd. (JP) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| CN-100443472-C | 3-alkylidenehydrazino substituted heteroaryl compound and medicine containing the same | NISSAN CHEMICAL IND LTD (JP) | 2008-12-17 | — | — | CN | disclosed |
| CN-101316853-A | Benzothiazole and thiazolopyridine as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC (US) | 2008-12-03 | — | — | CN | disclosed |
| CN-101282974-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC (US) | 2008-10-08 | — | — | CN | disclosed |
| CN-101282761-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC (US) | 2008-10-08 | — | — | CN | disclosed |
| CN-101277965-A | Imidazo [2, 1-b ] thiazole derivatives as SIRTUIN modulating compounds | SIRTRIS PHARMACEUTICALS INC (US) | 2008-10-01 | — | — | CN | disclosed |
| CN-101277963-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTIS PHARMACEUTICALS INC (US) | 2008-10-01 | — | — | CN | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| EP-1532134-B1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA SA (FR) | 2008-06-04 | — | — | EP | disclosed |
| EP-1909910-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910362-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910385-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910380-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910384-A1 | IMIDAZO [2,1-B]THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080076806-A1 | Di-aromatic substituted amides as inhibitors for GlyT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | US | disclosed |
| US-7345178-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2008022938-A1 | DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| US-20080045517-A1 | 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH) | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045517-A1 | 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH) | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| CN-101111483-A | IGF-1R inhibitors | KYOWA HAKKO KOGYO KK (JP) | 2008-01-23 | — | — | CN | disclosed |
| US-7297168-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297168-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297168-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| WO-2007128410-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| EP-1847532-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | MERCK HDAC RESEARCH, LLC | 2007-09-13 | — | — | US | disclosed |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | MERCK HDAC RESEARCH, LLC | 2007-09-13 | — | — | US | disclosed |
| US-7268158-B2 | 6H-THIENO [2,3-b]pyrrole derivatives as antagonists of gonadotropin releasing hormone (GnRH) | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-7268158-B2 | 6H-THIENO [2,3-b]pyrrole derivatives as antagonists of gonadotropin releasing hormone (GnRH) | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| EP-1461335-B1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007018508-A1 | NOVEL M3 MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007018508-A1 | NOVEL M3 MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007018514-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019345-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| CN-1913865-A | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE (US) | 2007-02-14 | — | — | CN | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| EP-1737417-A2 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter and Gamble Company (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| WO-2006065788-A2 | NOVEL MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065755-A2 | QUATERNARY AMMONIUM SALTS OF FUSED HETEAROMATIC AMINES AS NOVEL MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| EP-1594852-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2005-11-16 | — | — | EP | disclosed |
| CN-1223593-C | Preparation of Leiliqusai | LUNAN PHARM CO LTD (CN) | 2005-10-19 | — | — | CN | disclosed |
| CN-1223593-C | Preparation of Leiliqusai | LUNAN PHARM CO LTD (CN) | 2005-10-19 | — | — | CN | disclosed |
| US-6956040-B2 | Oxazolidinone piperazinyl derivatives as potential antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2005-10-18 | — | — | US | disclosed |
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-10-06 | — | — | US | disclosed |
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-09-15 | — | — | US | disclosed |
| WO-2005082892-A2 | TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005074875-A2 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2005-07-14 | — | — | US | disclosed |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | FMR LLC | 2005-06-02 | — | — | US | disclosed |
| EP-1532134-A1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | Aventis Pharma S.A. (FR) | 2005-05-25 | — | — | EP | disclosed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-02-03 | — | — | US | disclosed |
| WO-2005007625-A2 | HETEROCYCLIC AMIDES WITH ANTI-TUBERCULOSIS ACTIVITY | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-01-27 | — | — | WO | disclosed |
| CN-1186346-C | Thienopyrrolidinones | HOFFMANN LA ROCHE (CH) | 2005-01-26 | — | — | CN | disclosed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| US-20040254162-A1 | Oxazolidinone derivatives as antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-16 | — | — | US | disclosed |
| EP-1301517-B1 | THIENOPYRROLIDINONES | HOFFMANN LA ROCHE (CH) | 2004-12-15 | — | — | EP | disclosed |
| CN-1552709-A | Preparation of Leiliqusai | 鲁南制药股份有限公司 | 2004-12-08 | — | — | CN | disclosed |
| CN-1552709-A | Preparation of Leiliqusai | 鲁南制药股份有限公司 | 2004-12-08 | — | — | CN | disclosed |
| US-20040242591-A1 | Oxazolidinone derivatives as pontential antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-02 | — | — | US | disclosed |
| CN-1549714-A | Aminoisoxazole derivatives active as kinase inhibitors | — | 2004-11-24 | — | — | CN | disclosed |
| EP-1461335-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2004069816-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-19 | — | — | WO | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| US-20040127477-A1 | Heterocyclic glycyl beta-alanine derivatives | G. D. SEARLE & CO. (US) | 2004-07-01 | — | — | US | disclosed |
| US-6734307-B2 | USE AGAINST MULTIPLY RESISTANT GRAM POSITIVE PATHOGENS; HAVE A DIAZINE MOIETY ATTACHED TO THE PHENYLOXAZOLIDINONE WHICH IS FURTHER SUBSTITUTED BY HETEROCYCLIC, ARYL, SUBSTITUTED ARYL, HETEROAROAMATIC RING | RANBAXY LABORATORIES LIMITED (IN) | 2004-05-11 | — | — | US | disclosed |
| EP-1409464-A1 | OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2004-04-21 | — | — | EP | disclosed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-6689754-B1 | PIPERIDINE OR PYRIDINE DERIVATIVES; ALPHA V BETA 3 INTEGRIN ANTAGONISTS | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | disclosed |
| WO-2004007477-A1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | WO | disclosed |
| CN-1447808-A | Oxazolidinone derivatives as anticrobials | RANBAXY LAB LTD (IN) | 2003-10-08 | — | — | CN | disclosed |
| EP-0934264-B1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER (US) | 2003-09-10 | — | — | EP | disclosed |
| CN-1440412-A | Thienopyrrolidinones | HOFFMANN LA ROCHE (CH) | 2003-09-03 | — | — | CN | disclosed |
| WO-2003055878-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
| US-20030119817-A1 | Oxazolidinone derivatives as potential antimicrobials | MEHTA ANITA (IN) | 2003-06-26 | — | — | US | disclosed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1303511-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2003-04-23 | — | — | EP | disclosed |
| EP-1301517-A1 | THIENOPYRROLIDINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-16 | — | — | EP | disclosed |
| US-6528653-B2 | E.g., 4,6-dihydro 4-(heterocyclic ring-methylene)thieno(2,3-b) pyrrolidin-5-one derivatives; tumor necrosis factor ) inhibitors; anticarcinogenic, -proliferative and -arthritic agents; Alzheimer's disease; cardiovascular disorders | HOFFMANN-LA ROCHE, INC. | 2003-03-04 | — | — | US | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003008389-A1 | OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2003-01-30 | — | — | WO | disclosed |
| EP-0885205-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-20020103186-A1 | Oxazolidinone derivatives as antimicrobials disease | RANBAXY LABORATORIES LIMITED (IN) | 2002-08-01 | — | — | US | disclosed |
| CN-1355811-A | Integrain receptor antagaonists | BASF AG (DE) | 2002-06-26 | — | — | CN | disclosed |
| US-20020028841-A1 | Thienopyrrolidinones | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | US | disclosed |
| WO-2002006278-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2002-01-24 | — | — | WO | disclosed |
| EP-1173468-A1 | INTEGRIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2002002567-A1 | THIENOPYRROLIDINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | disclosed |
| US-6313302-B2 | OPIOID KAPPA RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; ANALGESICS, ANTIINFLAMMATORY AGENTS, ANESTHETICS, AND NEUROPROTECTANTS | PFIZER INC. | 2001-11-06 | — | — | US | disclosed |
| US-6310061-B2 | OPIOID RECEPTOR SUBTYPE KAPPA; USE AS ANALGESIC, ANESTHETIC, ANTIINFLAMMATORY OR NEUROPROTECTIVE AGENT, FOR TREATMENT OF ARTHRITIS, STROKE OR FUNCTIONAL BOWEL DISEASE; REDUCED DRUG DEPENDENCY SIDE EFFECTS | PFIZER INC. | 2001-10-30 | — | — | US | disclosed |
| US-6307061-B2 | USEFUL AS AN ANALGESIC, ANESTHETIC, ANTI-INFLAMMATORY OR NEUROPROTECIVE AGENT | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6303602-B1 | USEFUL AS ANALGESIC, ANESTHETIC, ANTI-INFLAMMATORY OR NEUROPROTECTIVE AGENT, OR FOR THERAPY OF ARTHRITIS, STROKE OF FUNCTIONAL BOWEL DISEASE | PFIZER INC. | 2001-10-16 | — | — | US | disclosed |
| US-6294557-B1 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-6294569-B2 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-20010020024-A1 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists | ITO FUMITAKA (JP) | 2001-09-06 | — | — | US | disclosed |
| US-20010014683-A1 | Analgesics; side effect reduction | ITO FUMITAKA (JP) | 2001-08-16 | — | — | US | disclosed |
| US-20010011091-A1 | Analgesics | ITO FUMITAKA (JP) | 2001-08-02 | — | — | US | disclosed |
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | ITO FUMITAKA (JP) | 2001-07-26 | — | — | US | disclosed |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | ITO FUMITAKA (JP) | 2001-07-19 | — | — | US | disclosed |
| CN-1304406-A | Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists | SEARLE & CO (US) | 2001-07-18 | — | — | CN | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6201007-B1 | OPIOID KAPPA RECEPTOR AGONISTS; ANALGESICS, ANESTHETICS, NEUROPROTECTIVE AND ANTIINFLAMMATORY AGENTS; STROKES, GASTROINTESTINAL DISORDERS | PFIZER INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1070060-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. Searle & Co. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000066618-A1 | INTEGRIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | disclosed |
| EP-0590885-B1 | Antibiotic carbapenem compounds | ZENECA LTD (GB) | 2000-03-15 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0592167-B1 | Antibiotic pyrrolidinylthiopenem derivatives | ZENECA LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| WO-1999052896-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0586663-B1 | CARBAPENEM DERIVATIVES AS ANTIBIOTICS AND INTERMEDIATES THEREOF | ZENECA LTD (GB) | 1999-09-29 | — | — | EP | disclosed |
| EP-0912175-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-09-08 | — | — | EP | disclosed |
| EP-0934264-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0912175-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| US-5854245-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0885205-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5840917-A | ADMINISTERING TO MAMMAL TO ERADICATE HELICOBACTER PYLORI | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| WO-1998042347-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A PHOSPHORYLAMIDE AND AN AYNTIBIOTIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-01 | — | — | WO | disclosed |
| EP-0852498-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| US-5780480-A | THROMBOLYTIC AGENTS, ANTICOAGULANTS | MERCK & CO., INC. (US) | 1998-07-14 | — | — | US | disclosed |
| US-5776859-A | DIALKYLAMINOMETHYL 5-AMINO-2-THIOPHENECARBOXYLATE | DR. N'S HEALTH CARE PRODUCTS LLC | 1998-07-07 | — | — | US | disclosed |
| WO-1998012177-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (JP) | 1998-03-26 | — | — | WO | disclosed |
| WO-1998000134-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| CN-1036713-C | Antibiotic compounds | ZENECA LTD (GB) | 1997-12-17 | — | — | CN | disclosed |
| WO-1997031910-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997018200-A1 | SODIUM CHANNEL ACTIVE NOVEL COMPOUNDS AND RELATED PROCESSES AND BIOASSAY TECHNIQUES | NICKEL ALFRED A (US) | 1997-05-22 | — | — | WO | disclosed |
| WO-1997011705-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
| EP-0661260-B1 | New bi-aromatic compounds derived from amides pharmaceutical compositions and cosmetic compositions containing them and their use | CIRD GALDERMA (FR) | 1997-03-12 | — | — | EP | disclosed |
| US-5571805-A | FOR TREATING BACTERIAL INFECTIONS IN MAMMALS | ZENECA LIMITED (GB) | 1996-11-05 | — | — | US | disclosed |
| US-5538962-A | PENICILLINS | ZENECA LIMITED (GB) | 1996-07-23 | — | — | US | disclosed |
| US-5527791-A | Carbapenem antibiotic compounds | ZENECA LIMITED (GB) | 1996-06-18 | — | — | US | disclosed |
| US-5519015-A | BACTERICIDES | ZENECA LIMITED (GB) | 1996-05-21 | — | — | US | disclosed |
| EP-0661260-A1 | New bi-aromatic compounds derived from amides pharmaceutical compositions and cosmetic compositions containing them and their use | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1995-07-05 | — | — | EP | disclosed |
| EP-0592167-A1 | Antibiotic pyrrolidinylthiopenem derivatives | ZENECA LIMITED (GB) | 1994-04-13 | — | — | EP | disclosed |
| EP-0590885-A1 | Antibiotic carbapenem compounds | ZENECA LIMITED (GB) | 1994-04-06 | — | — | EP | disclosed |
| EP-0586663-A1 | CARBAPENEM DERIVATIVES AS ANTIBIOTICS AND INTERMEDIATES THEREOF | ZENECA LIMITED (GB) | 1994-03-16 | — | — | EP | disclosed |
| CN-1077957-A | Antimicrobial compounds | ZENECA LTD (GB) | 1993-11-03 | — | — | CN | disclosed |
| WO-1993019070-A1 | CARBAPENEM DERIVATIVES AS ANTIBIOTICS AND INTERMEDIATES THEREOF | ZENECA LIMITED (GB) | 1993-09-30 | — | — | WO | disclosed |
| EP-0562855-A1 | Carbapenem compounds as antibiotics | ZENECA LIMITED (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0186252-B1 | USE OF THIOPHENE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT AGAINST TUMOURS | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1992-04-01 | — | — | EP | disclosed |
| US-4767758-A | RADIOSENSITIZING CELLS; BLOCKING REACTION OF OXYGEN RADICALS | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1988-08-30 | — | — | US | disclosed |
| EP-0186252-A2 | Use of thiophene compounds for the manufacture of a medicament against tumours | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1986-07-02 | — | — | EP | disclosed |
| US-4588817-A | Antibiotic nodusmicins | THE UPJOHN COMPANY (US) | 1986-05-13 | — | — | US | disclosed |
| US-4461903-A | Antibiotic nodusmicin derivatives | THE UPJOHN COMPANY (US) | 1984-07-24 | — | — | US | disclosed |
| US-4448970-A | ANTIBIOTICS, BACTERICIDES | THE UPJOHN COMPANY (US) | 1984-05-15 | — | — | US | disclosed |
| US-4363922-A | Esters of antibiotic nodusmicin | THE UPJOHN COMPANY (US) | 1982-12-14 | — | — | US | disclosed |
| US-4360683-A | Antibiotic nodusmicin derivatives | THE UPJOHN COMPANY (US) | 1982-11-23 | — | — | US | disclosed |
| US-4351769-A | Antibiotic composition of matter | THE UPJOHN COMPANY (US) | 1982-09-28 | — | — | US | disclosed |
| US-4220793-A | Process for preparing a thiophene derivative | LABAZ (FR) | 1980-09-02 | — | — | US | disclosed |
| US-4220793-A | Process for preparing a thiophene derivative | LABAZ (FR) | 1980-09-02 | — | — | US | disclosed |
| US-4093622-A | Pyridine esters of cyclopropane-carboxylic acid | ZOECON CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
| US-4093622-A | Pyridine esters of cyclopropane-carboxylic acid | ZOECON CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285382-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | SMN1; SMN2 326/4885HTT 250/4885LMNA 1436/4885 |
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | SMN1; SMN2 1572/4885HTT 234/4885LMNA 3414/4885 |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | SMN1; SMN2 2766/4885HTT 2134/4885LMNA 3334/4885 |
| US-20030119817-A1 | Oxazolidinone derivatives as potential antimicrobials | OXA1L, PDK4, SDHA | SMN1; SMN2 3652/4885HTT 2304/4885LMNA 3345/4885 |
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | SMN1; SMN2 2213/4885HTT 2081/4885LMNA 1925/4885 |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | SMN1; SMN2 1612/4885HTT 1201/4885LMNA 2808/4885 |
| US-20250114466-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | SMN1; SMN2 4478/4885HTT 1967/4885LMNA 4482/4885 |
| US-20080045517-A1 | 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH) | GNRHR, PRLHR, GHRHR | SMN1; SMN2 4706/4885HTT 725/4885LMNA 4783/4885 |
| US-20230105935-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SARS1, RNMT, EIF2AK2 | SMN1; SMN2 2570/4885HTT 2651/4885LMNA 444/4885 |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | SMN1; SMN2 2016/4885HTT 2565/4885LMNA 4688/4885 |
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | SMN1; SMN2 326/4885HTT 250/4885LMNA 1436/4885 |
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | CTSZ, CTSE, CTSS | SMN1; SMN2 4779/4885HTT 367/4885LMNA 4490/4885 |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | SMN1; SMN2 1178/4885HTT 144/4885LMNA 2798/4885 |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | SMN1; SMN2 2170/4885HTT 2445/4885LMNA 4738/4885 |
| US-20040127477-A1 | Heterocyclic glycyl beta-alanine derivatives | ITGB3, ITGAL, ITGB1 | SMN1; SMN2 811/4885HTT 4453/4885LMNA 972/4885 |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | SMN1; SMN2 1572/4885HTT 234/4885LMNA 3414/4885 |
| US-20160297789-A1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | RNASE1, IAPP, TESK1 | SMN1; SMN2 62/4885HTT 997/4885LMNA 2375/4885 |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | SMN1; SMN2 3990/4885HTT 4129/4885LMNA 3957/4885 |
| US-20040242591-A1 | Oxazolidinone derivatives as pontential antimicrobials | PDK4, OXA1L, PPARD | SMN1; SMN2 3962/4885HTT 1326/4885LMNA 3499/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | SMN1; SMN2 1160/4885HTT 381/4885LMNA 3283/4885 |
| US-20190241570-A1 | NOVEL DIHYDROPYRROLOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | DPYD, HAVCR2, QDPR | SMN1; SMN2 3699/4885HTT 4407/4885LMNA 3825/4885 |
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, NDUFS5 | SMN1; SMN2 4707/4885HTT 3005/4885LMNA 4363/4885 |
| US-20180127401-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, PNPO, VASP | SMN1; SMN2 3201/4885HTT 1401/4885LMNA 2253/4885 |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | SMN1; SMN2 326/4885HTT 250/4885LMNA 1436/4885 |
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | OPRL1, OPRD1, OPRK1 | SMN1; SMN2 1538/4885HTT 1344/4885LMNA 2522/4885 |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | SMN1; SMN2 326/4885HTT 250/4885LMNA 1436/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | SMN1; SMN2 1967/4885HTT 2555/4885LMNA 4674/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | SMN1; SMN2 2197/4885HTT 1904/4885LMNA 2068/4885 |
| US-20010011091-A1 | Analgesics | OPRL1, OPRK1, OPRD1 | SMN1; SMN2 3083/4885HTT 1009/4885LMNA 841/4885 |
| US-20020103186-A1 | Oxazolidinone derivatives as antimicrobials disease | OXA1L, MLYCD, TBCD | SMN1; SMN2 2876/4885HTT 1512/4885LMNA 2018/4885 |
| US-12415793-B2 | Modulators of TMEM16A for treating respiratory disease | TMEM109, CFTR, TMEM120A | SMN1; SMN2 1695/4885HTT 2832/4885LMNA 2052/4885 |
| US-20170044183-A1 | FACTOR XIa INHIBITORS | F11, SERPINC1, TFPI | SMN1; SMN2 4591/4885HTT 4136/4885LMNA 386/4885 |
| US-10421742-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | SMN1; SMN2 2641/4885HTT 1354/4885LMNA 1401/4885 |
| US-10093683-B2 | Factor XIa inhibitors | F11, F12, SERPINC1 | SMN1; SMN2 4445/4885HTT 4262/4885LMNA 394/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | SMN1; SMN2 2251/4885HTT 2095/4885LMNA 1857/4885 |
| US-20200172531-A1 | Novel compound and pharmaceutical composition containing the same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12, ZYX | SMN1; SMN2 2228/4885HTT 4507/4885LMNA 3509/4885 |
| US-11174253-B2 | Compound and pharmaceutical composition containing the same | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | SMN1; SMN2 1278/4885HTT 3980/4885LMNA 3014/4885 |
| US-20080076806-A1 | Di-aromatic substituted amides as inhibitors for GlyT-1 | AGXT, SLC1A2, GRIA1 | SMN1; SMN2 2156/4885HTT 226/4885LMNA 3382/4885 |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | SMN1; SMN2 4478/4885HTT 1967/4885LMNA 4482/4885 |
| US-11730729-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | SMN1; SMN2 326/4885HTT 250/4885LMNA 1436/4885 |
| US-11180471-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | SMN1; SMN2 2641/4885HTT 1354/4885LMNA 1401/4885 |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | SMN1; SMN2 2641/4885HTT 1354/4885LMNA 1401/4885 |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | SMN1; SMN2 326/4885HTT 250/4885LMNA 1436/4885 |
| US-20220098164-A1 | MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE | TMEM109, CFTR, TMEM120A | SMN1; SMN2 1695/4885HTT 2832/4885LMNA 2052/4885 |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | CHRNA2, CHRNA7, CHRNA3 | SMN1; SMN2 620/4885HTT 2624/4885LMNA 2429/4885 |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | SMN1; SMN2 326/4885HTT 250/4885LMNA 1436/4885 |
| US-20260125356-A1 | TREATMENT OF LEISHMANIASIS | NR1H2, NR1H3, MSR1 | SMN1; SMN2 1833/4885HTT 4861/4885LMNA 1064/4885 |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | CSNK1G1, PRKCE, PHKG1 | SMN1; SMN2 3119/4885HTT 3600/4885LMNA 1745/4885 |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | SMN1; SMN2 3716/4885HTT 2118/4885LMNA 4183/4885 |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | GRM5, GRIK5, GRM3 | SMN1; SMN2 786/4885HTT 834/4885LMNA 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.